- Home
- REFI vs RZLT Comparison
REFI vs RZLT Comparison
Compare REFI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- RZLT
- Stock Information
- Founded
- REFI 2021
- RZLT 2010
- Country
- REFI United States
- RZLT United States
- Employees
- REFI N/A
- RZLT N/A
- Industry
- REFI Real Estate Investment Trusts
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- RZLT Health Care
- Exchange
- REFI Nasdaq
- RZLT Nasdaq
- Market Cap
- REFI 306.1M
- RZLT 292.0M
- IPO Year
- REFI 2021
- RZLT N/A
- Fundamental
- Price
- REFI $16.16
- RZLT $4.98
- Analyst Decision
- REFI Strong Buy
- RZLT Strong Buy
- Analyst Count
- REFI 3
- RZLT 8
- Target Price
- REFI $20.00
- RZLT $11.63
- AVG Volume (30 Days)
- REFI 118.5K
- RZLT 373.9K
- Earning Date
- REFI 11-07-2024
- RZLT 02-11-2025
- Dividend Yield
- REFI 11.63%
- RZLT N/A
- EPS Growth
- REFI N/A
- RZLT N/A
- EPS
- REFI 2.00
- RZLT N/A
- Revenue
- REFI $56,860,278.00
- RZLT N/A
- Revenue This Year
- REFI N/A
- RZLT N/A
- Revenue Next Year
- REFI $4.27
- RZLT N/A
- P/E Ratio
- REFI $8.08
- RZLT N/A
- Revenue Growth
- REFI 6.49
- RZLT N/A
- 52 Week Low
- REFI $14.82
- RZLT $0.88
- 52 Week High
- REFI $17.65
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- REFI 56.28
- RZLT 44.97
- Support Level
- REFI $15.69
- RZLT $4.07
- Resistance Level
- REFI $16.24
- RZLT $4.68
- Average True Range (ATR)
- REFI 0.20
- RZLT 0.33
- MACD
- REFI -0.02
- RZLT -0.01
- Stochastic Oscillator
- REFI 79.03
- RZLT 37.50
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.